Compare Cassava Sciences Inc (FLNA) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Uranium Energy Corp — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Uranium Energy Corp trades at $9.2 (market cap $4.53B). The key difference: Uranium Energy Corp is far larger — about 115× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 10,888,578). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Uranium Energy Corp for 37 Days on average.
| FLNA | UEC | |
|---|---|---|
Market Cap | $39.40M | $4.53B |
Volume | 759,018 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $4.64 | $20.14 |
52-Week Low | $0.68 | $9.04 |
Typical Hold Time | 37 Days | 37 Days |
Enterprise Value | -$43.28M | $4.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
UEC trades at $9.27, down 2.11% on the day, amid a bearish technical outlook with 18 sell signals versus 2 buy signals. The company reported a net loss of $87.66 million in 2025, with revenue of $66.84 million, and a negative net income margin of -368.62%. Recent news highlights operational expansion with two in-situ recovery mines ramping up production, supported by strong institutional analyst sentiment with 7 buy ratings and a consensus price target of $16.06.
The investment case balances Wall Street optimism against weak profitability and cash burn. Upside is driven by exposure to growing U.S. uranium demand and multi-mine expansion, but high execution risk, sustained losses, and negative operating cash flow pose significant threats to shareholder value. The stock's trajectory hinges on translating production growth into sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
